When determining the maximum price and the
reimbursement level of medicinal products in the Czech Republic, the principle
of external price referencing (EPR) is applied. The principles of external
price referencing in the Czech context are set out in Act No. 48/1997 Coll., on
Public Health Insurance and on Amendments and Supplements to Certain Related
Acts.
The foundation of this approach is the comparison of the ex-factory prices of a given medicinal product across EU countries, with the final maximum price in
the Czech Republic derived based on these references. It is important to note
that EPR conditions and methodologies vary across the EU and a uniform approach
has not yet been adopted. Each country has its own specific rules and lists of
countries it references in its EPR system.
To support understanding, we have created an interactive
map that visualizes the countries involved in the EPR system as applied in the
Czech Republic. This tool provides a quick overview of which countries are
considered when determining the maximum price and the
reimbursement level of medicinal products in the Czech setting.
🔍 Map
features:
Display
of countries used as reference when determining reimbursement levels
Overview
of national price databases
Distinction
between countries used in the reference basket for the manufacturer’s
maximum price
Clear
color coding for easy navigation
This map is a useful tool for:
Professionals
in the pharmaceutical industry
Health
policy analysts
Pricing
and reimbursement regulators
And
anyone interested in the dynamics of European pharmaceutical pricing
strategies
Starting january 1, 2025, Pharmeca a.s. will provide an overview of issued decisions by the State Institute for Drug Control (SÚKL) and the Ministry of Health of the Czech Republic (MZ ČR) related to pricing and reimbursement on its website.
For marketing authorization holders, knowledge of SÚKL and MZ ČR decisions in the area of pricing and reimbursement is essential. The outcomes of individual proceedings shape decision-making practices that influence future decisions.
To address this need, Pharmeca a.s. now offers an interactive overview of decisions issued in the past five weeks.
Drug pricing and reimbursement are based on price referencing, where the foreign price in a foreign currency is converted into Czech koruna. For this purpose, it is essential to obtain the quarterly average exchange rate for the foreign exchange market, as published by the Czech National Bank.
Our new online overview provides: ✔ The required average exchange rate from the previous quarter ✔ The exchange rate development in the current quarter ✔ A monitoring focus on the 7 most commonly used European exchange rates in administrative proceedings
The key information for conducting price referencing in administrative procedures for drug pricing and reimbursement is the average exchange rate from the previous quarter. Now, you can easily...